• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATX 0.00% 6.2¢

AMPLIA THERAPEUTICS LIMITED

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company’s pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
ATX 07:14 3 597
07:14 Last post  Dimitrios63 Comments Created with Sketch.  3  Views Created with Sketch.  597 
ATX 02/05/24 5 1K
02/05/24 Last post  brrrattt Comments Created with Sketch.  5  Views Created with Sketch.  1K 
ATX
Unfair treatment to Non Aus shareholders
24/04/24 2 661
24/04/24 Last post  markwhite Comments Created with Sketch.  2  Views Created with Sketch.  661 
ATX 23/04/24 44 11K
23/04/24 Last post  petesherl Comments Created with Sketch.  44  Views Created with Sketch.  11K 
ATX 22/04/24 21 6.1K
22/04/24 Last post  leveller Comments Created with Sketch.  21  Views Created with Sketch.  6.1K 
ATX
News: ATX Amplia Therapeutics Says Fully Underwritten 2 For 5 Entitlement Offer
16/04/24 0 169
16/04/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  169 
ATX 16/04/24 0 190
16/04/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  190 
ATX 16/04/24 0 189
16/04/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  189 

See All Discussions arrow Created with Sketch.

Timeline

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 08:29
 
Entitlement Offer - Offer Booklet
24 Apr 12:32
 
Proposed issue of securities - ATX
16 Apr 10:08
 
Entitlement Offer Cleansing Statement
16 Apr 10:08
 
Rights Issue Investor Slide Deck
16 Apr 10:08
 
Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
16 Apr 10:07
 
View More arrow Created with Sketch.
(20min delay)
Last
6.2¢
Change
0.000(0.00%)
Mkt cap ! $12.02M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 150000 6.1¢
 

Sellers (Offers)

Price($) Vol. No.
6.2¢ 180369 2
View Market Depth
Last trade - 16.12pm 03/05/2024 (20 minute delay) ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.